Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
1,296 people get ACHN articles and Market Currents by email alert.
Get email alerts on ACHN »
FOCUS
|
PRO
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Watch Achillion Pharmaceuticals For Upcoming Phase IIa DataBrian L. Wilson • Tue, Apr 3, 2012 -
-
-
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
3 Stocks Upgraded On September 19 To ConsiderJorge Aura • Fri, Sep 21, 2012 -
-
-
-
-
-
GlobeNewswire (Jun 12, 2013)
-
GlobeNewswire (May 30, 2013)
-
GlobeNewswire (May 15, 2013)
-
GlobeNewswire (May 9, 2013)
-
GlobeNewswire (May 7, 2013)
-
GlobeNewswire (Apr 23, 2013)
-
GlobeNewswire (Apr 16, 2013)
-
GlobeNewswire (Mar 1, 2013)
-
GlobeNewswire (Feb 27, 2013)
-
GlobeNewswire (Feb 21, 2013)
-
GlobeNewswire (Feb 20, 2013)
-
GlobeNewswire (Feb 20, 2013)
-
GlobeNewswire (Feb 19, 2013)
-
GlobeNewswire (Feb 8, 2013)
-
GlobeNewswire (Jan 17, 2013)
-
GlobeNewswire (Jan 7, 2013)
-
GlobeNewswire (Nov 30, 2012)
-
GlobeNewswire (Nov 13, 2012)
ACHN vs. ETF Alternatives
Company Description
Currently, there's no company description for ACHN.
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
-
Thursday, June 6, 5:30 PM
After-hours top gainers, as of 5:15 p.m.: CCUR +9%. AYR +8%. ANAD +6%. RLD +5%. TRN +5%.
After-hours top losers: BV -13%. MKTG -11%. JRCC -10%. TIVO -8%. ACHN -7%. 1 Comment [On the Move] -
Monday, June 3, 5:32 PM
After-hours top gainers, as of 5:15 p.m.: GIII +7%. CHUY +5%. FTNT +4%. QLIK +4%. ACHN +4%.
After-hours top losers: RECN -7%. LGND -7%. MXWL -6%. FSYS -5%. ARRY -5%. Comment! [On the Move] - Wednesday, May 29, 8:31 AM Achillion Pharmaceuticals (ACHN) falls 7.38% premarket after CEO Michael Kishbauch announces his retirement. The company says R&D Chief Milind Deshpande will be the new CEO. (PR) Comment! [Healthcare, On the Move]
- Tuesday, May 7, 12:23 PM Achillion Pharmaceuticals (ACHN -1.4%) slips today in spite of reporting a Q1 result that beat Street expectations this morning. The drug developer reported a net loss of $11.7M, or $0.14 per share, compared to consensus estimates of a loss of $0.15. No revenue was recognized during the quarter. However, losses were higher than the same period last year, which came in at a loss of $9.1M, or $0.13 per share, on revenues of $2.5M. Comment! [Healthcare, Earnings, On the Move]
- Tuesday, April 23, 8:55 AM Achillion Pharmaceuticals (ACHN) falls after announcing results from a Phase 2 trial for ACH-3102, a NS5A protein inhibitor. Shares off 3% premarket. 4 Comments [Healthcare, On the Move]
- Friday, February 22, 2:35 PM Achillion Pharmaceuticals (ACHN +3%) trades up after pricing its offering of 15M shares at $8.40, just a slight 1.2% discount to Thursday's close. The company plans to use the roughly $120M to continue clinical testing of its hepatitis C drugs as well as general corporate expenses. Comment! [Healthcare, On the Move]
- Wednesday, February 20, 7:30 PM Achillion Pharmaceuticals (ACHN): Q4 EPS of -$0.14 beats by $0.06. Revenue of $118K. Shares -7.4% AH. (PR) Comment! [Earnings, Breaking News, Healthcare, On the Move]
-
Wednesday, February 20, 6:01 PM
After-hours top gainers, as of 5:30 p.m.: PEGA +18%. SID +16%. MKTG +7%. MTG +7%. CAR +6%.
After-hours top losers: RBCN -19%. TSLA -8%. ACHN -8%. HPY -6%. TXRH -6%. Comment! [On the Move] - Wednesday, February 20, 4:19 PM Achillion Pharmaceuticals (ACHN) announces a $125M secondary offering. Citigroup and Leerink Swann are acting as joint book-runners. The offering is subject to market conditions, with the actual size and terms not yet disclosed. Shares -5.6% AH. Comment! [Healthcare, On the Move]
-
Monday, January 7, 12:45 PM
Midday top 10 gainers: PPHM +67%. MDCI +28%. DLGC +24%. EPOC +22%. BIOL +21%. RFIL +21%. BITA +16%. PRGN +15%. CHRM +15%. CBMX +15%.
Midday top 10 Losers: HILL -20%. ESI -17%. STP -13%. SWSH -11%. PGRX -11%. PSEM -11%. IHT -11%. CDXS -10%. ACHN -10%. NED -9%. Comment! [On the Move] - Monday, January 7, 8:31 AM Achillion's (ACHN +3.2%) ACH-3102 medicine for chronic hepatitis C viral infections, in combination with antiviral drug ribavirin, has performed well so far in a Phase 2a study of 8 patients. The treatment "resulted in the rapid reduction in HCV RNA accompanied by normalization of liver enzymes." The combo also appears to be safe and well tolerated. (PR) 2 Comments [Healthcare, On the Move]
- Wednesday, January 2, 10:14 AM SA author Regarded Solutions bangs the table for Achillion Pharmaceuticals (ACHN +5.1%), citing its "wonderful balance sheet" and its four hepatitis C drugs, which could, "for all intents and purposes," cure the illness if approved. Achillion's promise has brought it several upgrades and made it a potential takeover target. Comment! [Healthcare, On the Move]
- Monday, November 12, 2012, 1:43 PM Shares of Achillion (ACHN -11%) drop hard on the back of competitor Gilead's (GILD +12%) positive results from Phase 2 testing of its Hep C antiviral drug ribavirin. ACHN is developing its own hepatitis C virus treatment which has performed well in tests. Wells Fargo's Brian Abraham says ACHN is "well-positioned" to participate in the HCV market, and today's weakness creates a buying opportunity. Comment! [Healthcare, On the Move]
- Tuesday, October 16, 2012, 12:36 PM Achillion (ACHN +4.6%) gains on a price target increase to $17 from $12 at Deutsche Bank. The firm says liver abstracts from Bristol-Myers (BMY +0.6%) and Abbott (ABT +0.1%) bode well for the future success of ACHN's two drug combo regimens for the treatment of hepatitus C virus. The firm made similar comments yesterday about Gilead (GILD +1.6%). Comment! [Healthcare, On the Move]
- Friday, September 28, 2012, 12:30 PM Cowen thinks Achillion (ACHN +1.6%) is likely to be acquired by a biopharm company in need of a hep C pipeline, and considering yesterday's announcement of positive Phase 1a trial results for its drug ACH-3102, the risk/reward profile looks favorable. The company hosted an Analyst Day meeting to discuss ACH-3102 today, and Cowen thinks the company successfully made the case for differentiating it from other first generation hep C drugs. Comment! [Healthcare, On the Move]
-
Thursday, September 27, 2012, 9:10 AM
Premarket gainers: ROYL +38.46%. TPX +14.53%. THO +8.63%. ACHN +6.53%.
Losers: PPHM -23%. Comment! [On the Move]
-
- View all 0 replies
-
The Wall Street Transcript
Achillion Pharmaceuticals ($ACHN) Remains Undervalued Relative to Gilead ($GILD)- http://su.pr/2KWM0O - View all 0 replies
-
- View all 0 replies
-
Regarded Solutions
The Young And Restless Portfolio: Adding A Tiny Biopharma Stock http://bit.ly/XeGPjr $ACHN - View all 0 replies
-
Adam Gefvert
Short $ACHN. I never liked the company, and it has gone up way too far way too fast on no news, only opinions. - View all 0 replies
-
freefdawatchlist
http://stks.co/fBP2 Premarket loser $IDIX, $GTAT, $KLAC, $LRCX, Premarket gainer $ACHN, $CY, $DRYS, $CBRL - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
Scott Matusow
$ACHN $PSDV could be on move today up. ACHN oversold reaction, In my opinion nice entry, PSDV under accumulation, buy out candidate. - View all 1 replies
-
cornerback2006: I bought in on ACHN, hoping they announce good Phase II results b/n now and Sunday, especially w/ the knee-jerk reaction yesterday...
-
Cockrell Group
Credit Suisse analyst Ravi Mehrotra starts coverage on: $VRTX, $ACHN, $MVIR'B-SFYK.PK, $IDIX http://bit.ly/HR3EXn - View all 0 replies
LATEST REPLIES
-
Scott Matusow
$ACHN $PSDV could be on move today up. ACHN oversold reaction, In my opinion nice entry, PSDV under accumulation, buy out candidate. - View all 1 replies
-
cornerback2006: I bought in on ACHN, hoping they announce good Phase II results b/n now and Sunday, especially w/ the knee-jerk reaction yesterday...
-
Scott Matusow
Achillion (ACHN) should move today with Phase 2b data expected soon on one of their drugs. - View all 4 replies
-
-
cornerback2006: sorry for the repeats, new at this..it seems to take a full 2 hrs for my comments to get posted...hope SA fixes this! Thks for the response
-
- View all 7 replies
-
-
phemale60: has some useful information but I guess they are also trying to push their Biotech Supertrader program. Love their "quote of the day"!